Plasma pyridoxal-5-phosphate and future risk of myocardial infarction in the European Prospective Investigation into Cancer and Nutrition Potsdam cohort.
BACKGROUND
Retrospective studies indicate that low concentrations of plasma pyridoxal-5-phosphate (PLP) are associated with cardiovascular events; however, few prospective studies of this issue have been conducted.


OBJECTIVE
We therefore investigated whether PLP concentrations are independently associated with myocardial infarction (MI) in the European Investigation into Cancer and Nutrition (EPIC) Potsdam Study.


METHODS
After exclusion of prevalent MI or stroke, incident cases of MI were identified among 26 761 participants (aged 35-65 y at baseline). The current analysis is based on a nested case-cohort study consisting of a control group of 810 subjects without MI or stroke at baseline and a case group of 148 subjects who had an MI during a mean follow-up period of 6.0 +/- 1.5 y. Cox proportional hazard models were used to evaluate the association between plasma PLP and risk of MI.


RESULTS
In the age- and sex-adjusted analysis, subjects in the highest quintile of PLP had a significantly reduced risk of MI (hazard ratio: 0.50; 95% CI: 0.29, 0.83). Adjustment for either low-grade inflammation or smoking diminished this association. When both low-grade inflammation and smoking were adjusted for, the association was abolished. In addition, adjustment for established risk factors also abolished the association between PLP and risk of MI.


CONCLUSIONS
These findings from a prospective German cohort study suggest that PLP is not independently associated with risk of MI.
Dierkes
Jutta
J
Institute of Clinical Chemistry and Biochemistry, University Hospital Magdeburg, Magdeburg, Germany. jutta.dierkes@medizin.uni-magdeburg.de
Weikert
Cornelia
C
Klipstein-Grobusch
Kerstin
K
Westphal
Sabine
S
Luley
Claus
C
Möhlig
Matthias
M
Spranger
Joachim
J
Boeing
Heiner
H
D000328:Adult; D000368:Aged; D001794:Blood Pressure / Q000502:physiology; D015992:Body Mass Index; D002097:C-Reactive Protein / Q000378:metabolism; D016022:Case-Control Studies; D008076:Cholesterol, HDL / Q000097:blood; D015331:Cohort Studies; D003404:Creatinine / Q000097:blood; D005260:Female; D005492:Folic Acid / Q000097:blood; D005858:Germany / Q000453:epidemiology; D006710:Homocysteine / Q000097:blood; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood* / Q000453:epidemiology; D016016:Proportional Hazards Models; D011446:Prospective Studies; D011732:Pyridoxal Phosphate / Q000097:blood*; D011795:Surveys and Questionnaires
D008076:Cholesterol, HDL; D006710:Homocysteine; D011732:Pyridoxal Phosphate; D002097:C-Reactive Protein; D005492:Folic Acid; D003404:Creatinine